Every Form 4 that Synergy CHC Corp. (SNYR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNYR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNYR filings page.
Synergy CHC Corp. director and president Alfred Baumeler re-priced a stock option award covering 150,000 shares of common stock. On this Form 4, a prior option for 150,000 shares with a $2.38 per share exercise price was canceled and a new option for 150,000 shares with a $0.21 per share exercise price was granted in its place.
According to the footnotes, this reduction in exercise price is treated under Section 16 as a cancellation and re-grant of the same award. The new option vests on the same schedule as the original option, with one-third vesting on the first anniversary of September 18, 2025 and the remaining two-thirds vesting in equal monthly installments over the following 24 months, subject to continued service. The new option expires on the five-year anniversary of the original grant date. These are compensation-related derivative transactions, with no reported open-market purchases or sales of common shares.
Synergy CHC Corp. Chief Financial Officer Jaime Fickett reported a restructuring of an existing stock option award. An original option covering 150,000 shares of common stock with a $2.38 exercise price was deemed canceled for Section 16 purposes, and a new option for 150,000 shares was granted with a reduced exercise price of $0.21 per share.
According to the footnotes, this reduction in exercise price is treated as a material modification, with the new option keeping the same vesting schedule and a five-year term from the original September 18, 2025 grant date. One-third of the option vests on the first anniversary of that date, and the remaining two-thirds vest in equal monthly installments over the following 24 months, subject to continued service.
Synergy CHC Corp. insider activity shows an option repricing for shares held indirectly through Kenek Brands Inc., which is controlled by CEO and Chairman Ross Jack. A stock option for 750,000 shares of common stock with a $2.38 exercise price was deemed canceled and disposed of back to the company.
On the same date, Kenek Brands Inc. received a new stock option covering 750,000 underlying shares at a reduced exercise price of $0.21 per share. The new option keeps the original vesting schedule tied to the September 18, 2025 grant date and expires on the five-year anniversary of that date. The filing notes Jack’s indirect beneficial ownership through Kenek Brands Inc., with beneficial ownership disclaimed except for his pecuniary interest.
Synergy CHC Corp. director Kaushal Nitin received a stock-based compensation award of 306,433 restricted stock units on common stock. The award was reported as a grant or other acquisition with no cash price per share. According to the terms, each RSU represents a contingent right to one common share and the RSUs vested in full on the grant date. Following this grant, Nitin directly holds 306,433 common shares associated with this award.
Synergy CHC Corp. director Teresa Brigid Thompson received an equity award of 25,824 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Synergy CHC common stock.
The RSUs were granted and fully vested on the grant date, with no cash exercise price. Following this award, Thompson holds 25,824 shares of common stock directly, reflecting a routine compensation-related grant under Synergy CHC’s 2024 Equity Incentive Plan.